<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688775</url>
  </required_header>
  <id_info>
    <org_study_id>19386A</org_study_id>
    <nct_id>NCT04688775</nct_id>
  </id_info>
  <brief_title>Eptinezumab in Participants With Episodic Cluster Headache</brief_title>
  <acronym>ALLEVIATE</acronym>
  <official_title>Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Delayed-Start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of eptinezumab in participants with&#xD;
      episodic Cluster Headache (eCH)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants will be randomly assigned to receive treatment, in a blinded manner,&#xD;
      two infusions of either eptinezumab or placebo in a cross-over manner during the&#xD;
      Placebo-controlled Period and Active Treatment Period of the study.&#xD;
&#xD;
      The total duration of the study is 24 weeks, including a safety follow-up period of 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">July 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Number of Weekly Attacks, Averaged Over Weeks 1-2</measure>
    <time_frame>Baseline, Weeks 1-2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥50% Reduction From Baseline in Number of Weekly Attacks</measure>
    <time_frame>Weeks 1-2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weekly Number of Times an Abortive Therapy Was Used, Averaged Over Weeks 1-2</measure>
    <time_frame>Baseline, Weeks 1-2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Daily Attacks, Averaged Over Days 1-3</measure>
    <time_frame>Baseline, Days 1-3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weekly Number of Days With Less Than 3 Attacks Per Day, Averaged Over Weeks 1-2</measure>
    <time_frame>Baseline, Weeks 1-2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Cluster Headache Bout Within 4 Weeks After the First Investigational Medicinal Product (IMP) Infusion</measure>
    <time_frame>From Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Attacks Starting Within 24 Hours of the Start of the First Infusion</measure>
    <time_frame>From first infusion (Day 0) to 24-hours post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Daily Mean Score on 5-Point Self-Rating Pain Severity Scale, Averaged Over Days 1-3</measure>
    <time_frame>Baseline, Days 1-3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 1 in Number of Attacks</measure>
    <time_frame>Baseline, Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 2 in Number of Attacks</measure>
    <time_frame>Baseline, Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥50% Reduction in Number of Attacks in Week 1</measure>
    <time_frame>Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥30% Reduction in Number of Attacks in Week 1</measure>
    <time_frame>Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥30% Reduction in Number of Weekly Attacks</measure>
    <time_frame>Weeks 1-2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weekly Integrated Measure of Frequency and Intensity of pain, Averaged Over Weeks 1-2</measure>
    <time_frame>Baseline, Weeks 1-2</time_frame>
    <description>For each week add the intensity (worst pain on 5-point self-rating pain severity scale) for each attack experienced during that week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 1 in Integrated Measure of Frequency and Intensity of Pain</measure>
    <time_frame>Baseline, Week 1</time_frame>
    <description>For Week 1 add the intensity (worst pain on 5-point self-rating pain severity scale) for each attack experienced during that week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 2 in Weekly Integrated Measure of Frequency and Intensity of Pain</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>For Week 2 add the intensity (worst pain on 5-point self-rating pain severity scale) for each attack experienced during that week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Weekly Attacks, Averaged Over Weeks 1-4</measure>
    <time_frame>Baseline, Weeks 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weekly Integrated Measure of Frequency and Intensity of Pain, Averaged Over Weeks 1-4</measure>
    <time_frame>Baseline, Weeks 1-4</time_frame>
    <description>For each week add the intensity (worst pain on 5-point self-rating pain severity scale) for each attack experienced during that week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Score on 5-Point Self-Rating Pain Severity Scale (Average Per Week) for Weeks 1, 2, 3, and 4</measure>
    <time_frame>Baseline, Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Attacks for Weeks 1, 2, 3, and 4</measure>
    <time_frame>Baseline, Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) Score at Weeks 1, 2, and 4</measure>
    <time_frame>Weeks 1, 2, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sleep Impact Scale (SIS) Domain Scores at Weeks 2 and 4</measure>
    <time_frame>Baseline, Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Euroqol 5-Dimension 5-Levels (EQ-5D-5L) Visual Analogue Scale (VAS) at Weeks 2 and 4</measure>
    <time_frame>Baseline, Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Resource Utilization (HCRU) Score at Week 4</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Work Productivity Activity Impairment (WPAI) Questionnaire Score at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>General Health second version (WPAI:GH2.0) sub-scores (Absenteeism, Presenteeism, Work productivity loss, Activity impairment)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Cluster Headache, Episodic</condition>
  <arm_group>
    <arm_group_label>Sequence 1: Eptinezumab Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eptinezumab in the Placebo-controlled Period, followed by administration of placebo in the Active Treatment Period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2: Placebo Then Eptinezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo in the Placebo-controlled Period, followed by administration of eptinezumab in the Active Treatment Period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eptinezumab</intervention_name>
    <description>Eptinezumab - concentrate for solution for infusion, intravenously</description>
    <arm_group_label>Sequence 1: Eptinezumab Then Placebo</arm_group_label>
    <arm_group_label>Sequence 2: Placebo Then Eptinezumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - 100 milliliters (mL) of 0.9% normal saline, intravenously</description>
    <arm_group_label>Sequence 1: Eptinezumab Then Placebo</arm_group_label>
    <arm_group_label>Sequence 2: Placebo Then Eptinezumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant has episodic cluster headache, as defined by International Headache&#xD;
             Society (IHS) International Classification of Headache Disorders 3rd Edition (ICHD-3)&#xD;
             classification, with a documented history of eCH of at least 12 months prior to&#xD;
             Screening Visit 1.&#xD;
&#xD;
          -  The participant has a prior history of cluster period(s) lasting 6 weeks or longer.&#xD;
&#xD;
          -  The participant is able to distinguish cluster headache attacks from other headaches&#xD;
             (that is; tension-type headaches, migraine).&#xD;
&#xD;
          -  The participant is, at Screening Visit 2, in cluster headache bout, characterized by&#xD;
             the presence of at least one typical cluster headache attack, that started not later&#xD;
             than 1 week prior to Screening Visit 2.&#xD;
&#xD;
          -  The participant has had a medical history of cluster headache from ≤50 years of age.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  The participant has experienced failure on a previous treatment targeting the&#xD;
             calcitonin gene-related peptide (CGRP) pathway (anti-CGRP monoclonal antibodies [mAbs]&#xD;
             and gepants).&#xD;
&#xD;
          -  The participant has confounding and clinically significant pain syndromes (for&#xD;
             example, fibromyalgia, complex regional pain syndrome).&#xD;
&#xD;
          -  The participant has a history or diagnosis of hypnic headache, hemicrania continua,&#xD;
             new daily persistent headache, chronic migraine or unusual migraine subtypes such as&#xD;
             hemiplegic migraine (sporadic and familial), recurrent painful ophthalmoplegic&#xD;
             neuropathy, migraine with brainstem aura and migraine with neurological accompaniments&#xD;
             that are not typical of migraine aura (diplopia, altered consciousness, or long&#xD;
             duration).&#xD;
&#xD;
          -  Participants with a lifetime history of psychosis, bipolar mania, or dementia are&#xD;
             excluded. Participants with other psychiatric conditions whose symptoms are not&#xD;
             controlled or who have not been adequately treated for a minimum of 6 months prior to&#xD;
             Screening Visit 2 are also excluded.&#xD;
&#xD;
          -  The participant is, at Screening Visit 2, at significant risk of suicide.&#xD;
&#xD;
          -  The participant has a history of clinically significant cardiovascular disease,&#xD;
             including uncontrolled hypertension, ischaemia or thromboembolic events (for example,&#xD;
             cerebrovascular accident, deep vein thrombosis, or pulmonary embolism).&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Neurosciences Health Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New England Institute for Neurology and Headache</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diamond Headache Clinic</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michigan Headache and Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104-5131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Headache Center Mississippi</name>
      <address>
        <city>Ridgeland</city>
        <state>Mississippi</state>
        <zip>39157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinvest Research</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dent Neurologic Institute - Amherst</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Headache Wellness Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hightower Clinical</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mestska Nemocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <state>Moravian-Silesian</state>
        <zip>728 80</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Neuropsychiatrické Péce</name>
      <address>
        <city>Praha 1</city>
        <state>Praha</state>
        <zip>110 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurologicka Ambulance - Forbeli</name>
      <address>
        <city>Praha 10</city>
        <zip>160 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultní Thomayerova nemocnice</name>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet Glostrup</name>
      <address>
        <city>Glostrup</city>
        <state>Hovedstaden</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospitalsenhed Midt og Regionshospitalet Viborg</name>
      <address>
        <city>Viborg</city>
        <state>Midtjylland</state>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Confido Meditsiinikeskus</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ida-Viru Keskhaigla</name>
      <address>
        <city>Kohtla-Järve</city>
        <state>Ida-Virumaa</state>
        <zip>31025</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampereen Yliopistollinen Sairaala</name>
      <address>
        <city>Tampere</city>
        <state>Länsi-Suomen Lääni</state>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Terveystalo Ruoholahti</name>
      <address>
        <city>Helsinki</city>
        <state>Southern Finland</state>
        <zip>00180</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Terveystalo Turku Pulssi</name>
      <address>
        <city>Turku</city>
        <state>Western Finland</state>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Terveystalo Tampere</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Cimiez</name>
      <address>
        <city>Nice Cedex 1</city>
        <state>Côte-d'Or</state>
        <zip>91179 - 06003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Wertheimer</name>
      <address>
        <city>Lyon</city>
        <state>Rhone-alpes</state>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Saint-Étienne</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <state>Rhône</state>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <state>ÃŽle-de-France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Archangel Saint Michael Multiprofile Clinical Hospital</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aversi Clinic - Central Branch</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Consilium Medulla Multiprofile Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum - Campus Grosshadern</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mediterraneo Hospital</name>
      <address>
        <city>Glyfada</city>
        <state>Attica</state>
        <zip>16675</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Patras Agios Andreas</name>
      <address>
        <city>Patra</city>
        <state>Western Greece</state>
        <zip>263 32</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <state>Florence</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana</name>
      <address>
        <city>Rome</city>
        <state>Roma</state>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Mondino - Istituto Neurologico Nazionale a Carattere Scientifico IRCCS</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universita Campus Bio-Medico di Roma</name>
      <address>
        <city>Rome</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitario Lisboa Norte - Hospital De Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <state>Lisboa</state>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Garcia de Orta</name>
      <address>
        <city>Almada</city>
        <zip>2805-267</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital da Luz</name>
      <address>
        <city>Lisboa</city>
        <zip>1500-650</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Hospital No. 33 of the Leninsky District of the city of Nizhny Novgorod</name>
      <address>
        <city>Nizhnij Novgorod</city>
        <state>Nizhegorodskaya Oblast</state>
        <zip>603076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Perm State Medical University n.a. Academician E.A. Wagner</name>
      <address>
        <city>Perm</city>
        <state>Permsky</state>
        <zip>614990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Moscow State Medical University named after I.M. Sechenov</name>
      <address>
        <city>Moscow</city>
        <zip>119146</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Headache Clinic</name>
      <address>
        <city>Moscow</city>
        <zip>121467</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>València</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huddinge Hospital</name>
      <address>
        <city>Huddinge</city>
        <state>Stockholms Län</state>
        <zip>141 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Walton Centre NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Newcastle Upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle-upon-Tyne</city>
        <state>England</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

